Ivan O Rosas Selected Research

COVID-19

10/2023	A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling.
9/2023	Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19.
1/2023	Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID-19.
12/2022	Fulminant lung fibrosis in non-resolvable COVID-19 requiring transplantation.
5/2022	Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).
1/2022	Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
11/2021	Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial.
1/2021	Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
1/2021	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ivan O Rosas Research Topics

Disease

34	Idiopathic Pulmonary Fibrosis 03/2024 - 06/2007
26	Pulmonary Fibrosis (Fibrosing Alveolitis) 04/2024 - 03/2010
25	Fibrosis (Cirrhosis) 12/2022 - 01/2008
19	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2023 - 07/2009
17	Lung Diseases (Lung Disease) 01/2024 - 01/2008
16	Chronic Obstructive Pulmonary Disease (COPD) 12/2023 - 09/2012
15	Rheumatoid Arthritis 01/2023 - 04/2013
13	Emphysema 12/2023 - 03/2011
12	Inflammation (Inflammations) 12/2023 - 07/2009
10	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 01/2023 - 01/2014
10	Lung Injury 12/2022 - 03/2012
9	COVID-19 10/2023 - 01/2021
6	Pneumonia (Pneumonitis) 05/2022 - 03/2012
5	Disease Progression 01/2023 - 10/2012
5	Neoplasms (Cancer) 10/2020 - 01/2014
3	Infections 01/2023 - 01/2016
3	Tuberous Sclerosis (Bourneville's Disease) 12/2019 - 01/2014
3	Dyspnea (Shortness of Breath) 03/2019 - 04/2012
2	Severe Acute Respiratory Syndrome 01/2023 - 05/2022
2	Hermanski-Pudlak Syndrome (Hermansky-Pudlak Syndrome) 06/2022 - 01/2018
2	Hypoxia (Hypoxemia) 04/2022 - 10/2015
2	Sepsis (Septicemia) 01/2022 - 12/2013
2	Respiratory Insufficiency (Respiratory Failure) 10/2021 - 01/2014
2	Critical Illness (Critically Ill) 01/2021 - 12/2013
2	Wounds and Injuries (Trauma) 10/2020 - 05/2016
2	Pulmonary Arterial Hypertension 01/2020 - 01/2018
2	Vascular Diseases (Vascular Disease) 01/2020 - 09/2017
2	Pulmonary Hypertension 01/2020 - 01/2018
2	Bronchiolitis Obliterans Syndrome 01/2017 - 01/2017
2	Carcinogenesis 01/2017 - 01/2014
1	Post-Acute COVID-19 Syndrome 01/2024
1	Cachexia 11/2023

Drug/Important Bio-Agent (IBA)

17	Biomarkers (Surrogate Marker)IBA 03/2024 - 04/2008
17	Proteins (Proteins, Gene)FDA Link 12/2023 - 01/2008
12	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 03/2010
9	SmokeIBA 01/2022 - 04/2012
7	RNA (Ribonucleic Acid)IBA 12/2023 - 01/2020
7	CollagenIBA 01/2023 - 03/2010
7	lipoarabinomannan (LAM)IBA 01/2023 - 01/2014
6	tocilizumab (atlizumab)FDA Link 09/2023 - 01/2021
5	pirfenidoneIBA 01/2023 - 02/2015
5	AntibodiesIBA 01/2023 - 07/2009
5	Syndecan-2IBA 01/2022 - 10/2013
5	Carbon MonoxideIBA 01/2022 - 07/2015
4	GoldIBA 12/2023 - 09/2015
4	nintedanibIBA 01/2023 - 02/2015
4	Sirolimus (Rapamycin)FDA Link 11/2018 - 01/2012
3	Rituximab (Mabthera)FDA Link 03/2024 - 01/2018
3	Interleukin-6 (Interleukin 6)IBA 10/2023 - 01/2021
3	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 09/2023 - 01/2021
3	Messenger RNA (mRNA)IBA 04/2022 - 01/2016
3	AntigensIBA 01/2022 - 04/2013
3	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2020 - 10/2013
3	CytokinesIBA 01/2020 - 07/2009
3	Blood Proteins (Serum Proteins)IBA 01/2020 - 07/2009
3	Hydroxyproline (4 Hydroxyproline)IBA 01/2020 - 01/2016
3	AutoantibodiesIBA 01/2020 - 04/2013
3	TOR Serine-Threonine KinasesIBA 12/2019 - 09/2015
3	brassIBA 03/2019 - 07/2014
2	Intravenous Immunoglobulins (IVIG)FDA Link 03/2024 - 02/2024
2	ChitinasesIBA 05/2023 - 01/2019
2	InterferonsIBA 01/2023 - 01/2021
2	Immunoglobulin A (IgA)IBA 01/2023 - 01/2020
2	remdesivirIBA 01/2023 - 11/2021
2	Monoclonal AntibodiesIBA 11/2022 - 01/2021
2	Peptides (Polypeptides)IBA 04/2022 - 09/2015
2	C-Reactive ProteinIBA 01/2022 - 07/2009
2	ChemokinesIBA 01/2022 - 07/2009
2	Oxygen (Dioxygen)IBA 11/2021 - 01/2008
2	LigandsIBA 01/2021 - 10/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 09/2015
2	Extracellular Matrix ProteinsIBA 01/2020 - 06/2007
2	Methotrexate (Mexate)FDA LinkGeneric 03/2019 - 01/2019
2	GlucocorticoidsIBA 01/2019 - 01/2018
2	Mucin-5BIBA 11/2018 - 06/2013
2	trans-sodium crocetinate (crocetin)IBA 01/2017 - 01/2014
2	Vascular Endothelial Growth Factor DIBA 01/2017 - 03/2014
2	Protein Isoforms (Isoforms)IBA 01/2016 - 04/2013
2	Galectin 3 (LGALS3)IBA 01/2016 - 03/2014
2	InflammasomesIBA 01/2016 - 03/2012
2	Matrix Metalloproteinases (MMPs)IBA 08/2014 - 07/2009
2	ImmunosorbentsIBA 04/2013 - 07/2009
2	EnzymesIBA 04/2013 - 07/2009
1	Immunologic Factors (Immunomodulators)IBA 01/2024
1	Proline (L-Proline)FDA Link 11/2023
1	Surface-Active Agents (Surfactants)IBA 11/2023
1	Niacin (Nicotinic Acid)FDA LinkGeneric 11/2023
1	phosphatidylethanolamineIBA 11/2023
1	Glutamic Acid (Glutamate)FDA Link 11/2023
1	Aspartic Acid (Aspartate)FDA Link 11/2023
1	Transfer RNA (tRNA)IBA 11/2023
1	Arginine (L-Arginine)FDA Link 11/2023
1	Niacinamide (Nicotinamide)FDA LinkGeneric 11/2023
1	Alanine (L-Alanine)FDA Link 11/2023
1	InterleukinsIBA 09/2023

Therapy/Procedure

7	Lung Transplantation 12/2022 - 11/2015
6	Therapeutics 02/2024 - 02/2013
3	Transplantation 12/2022 - 07/2009
2	Plasma Exchange 03/2024 - 02/2024
1	Precision Medicine 04/2024